Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Ivan Engel

Psychiatry Phoenix, AZ Medical Doctor

NPI 1598737363 CMS profile 522589

4451 E Oak St, Ste 100, Phoenix, AZ 85008

Open in the dashboard

General payments

$9,934

156 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Ivan Engel of Phoenix, AZ is reported in the CMS Open Payments database as having received $9,934 across 156 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $231 3
2021 General $1,201 39
2020 General $5,328 42
2019 General $3,174 72

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ivan Engel
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ivan Engel were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ivan Engel Psychiatry median Middle half National median
2019 $3,174 $184 $59–$605 $163
2020 $5,328 $119 $36–$372 $114
2021 $1,201 $143 $43–$576 $132
2022 $231 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Otsuka America Pharmaceutical, Inc. $5,265 29 payments
  2. Alkermes, Inc. $2,031 59 payments
  3. Sunovion Pharmaceuticals Inc. $932 22 payments
  4. Neurocrine Biosciences, Inc. $631 8 payments
  5. Janssen Pharmaceuticals, Inc $590 17 payments
  6. ITI, Inc. $186 14 payments
  7. Allergan Inc. $138 2 payments
  8. Indivior Inc. $117 3 payments
  9. Vanda Pharmaceuticals Inc. $44 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $5,666 149 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,019 2 payments
  3. Travel and Lodging $1,151 2 payments
  4. Education $98 3 payments
Products named General payments · program years 2019–2022
  1. ABILIFY MAINTENA $5,163 28 payments
  2. ARISTADA INITIO $1,525 52 payments
  3. ARISTADA Cns $1,525 52 payments
  4. ARISTADA Cns $1,525 52 payments
  5. ARISTADA Cns $1,481 48 payments
  6. ARISTADA Cns $1,481 48 payments
  7. REXULTI $1,451 8 payments
  8. LATUDA $932 22 payments
  9. INVEGA SUSTENNA $471 16 payments
  10. INGREZZA $393 6 payments
  11. Other $2,672 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

156 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record